Skip to main content
. 2010 May;64(6):763–774. doi: 10.1111/j.1742-1241.2010.02360.x

Table 3.

Number of patients with a dose increase or decrease after the first 2 weeks of the extension phase grouped by double-blind medication: analgesia study

Treatment during double-blind phase Decrease in dose, n (%) Increase in dose, n (%)
Oxycodone PR/naloxone PR
20 mg/10 mg 0 (0) 22 (37)
40 mg/20 mg 17 (24) 19 (27)
Oxycodone PR
20 mg 3 (5) 24 (37)
40 mg 8 (15) 18 (33)
Placebo
20 mg 2 (3) 33 (46)
40 mg 9 (17) 20 (38)

PR, prolonged release.